Allergy Therapeutics plc (LON:AGY – Get Free Report) shares reached a new 52-week low on Tuesday . The stock traded as low as GBX 6 and last traded at GBX 7.40, with a volume of 192326 shares changing hands. The stock had previously closed at GBX 6.80.
Allergy Therapeutics Price Performance
The firm has a market cap of £468.61 million, a PE ratio of -7.63, a P/E/G ratio of -30.70 and a beta of 0.87. The company has a debt-to-equity ratio of 629.58, a current ratio of 1.13 and a quick ratio of 1.48. The business’s fifty day moving average is GBX 8.33 and its 200-day moving average is GBX 10.05.
About Allergy Therapeutics
Allergy Therapeutics is an international commercial biotechnology company focussed on the treatment and diagnosis of allergic disorders, including aluminium free immunotherapy vaccines that have the potential to cure disease. The Group sells proprietary and third party products from its subsidiaries in nine major European countries and via distribution agreements in an additional ten countries. Its broad pipeline of products in clinical development include vaccines for grass, tree and house dust mite, and peanut allergy vaccine in pre-clinical development.
See Also
- Five stocks we like better than Allergy Therapeutics
- 3 Overlooked Energy ETFs Delivering Strong Returns and Income
- 3 Space Stocks That Could Outshine SpaceX After Its IPO
- JPMorgan’s Q2 Strength Gives the Stock Rally New Support
- 3 Energy Stocks Racing to Fix AI’s Power Problem
Receive News & Ratings for Allergy Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Allergy Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.
